[
  {
    "query_understanding": "MDD adult: dx criteria + meds",
    "diagnosis": {
      "name": "Major Depressive Disorder (Adult)",
      "codes": {"ICD10": "F32.x/F33.x", "ICD11": "6A70"},
      "core_criteria_summary": "≥2 weeks depressed mood or anhedonia plus ≥4: sleep change, appetite/weight, psychomotor, fatigue, guilt/worthlessness, concentration, suicidality; causes distress/impairment; no mania/hypomania.",
      "differential": ["Bipolar depression", "Grief", "Substance-induced", "Hypothyroidism"],
      "screeners": [{"name": "PHQ-9", "use": "severity & monitoring", "cutoffs": "5/10/15/20 = mild/mod/severe"}],
      "workup_considerations": ["Bipolar screen (MDQ) before antidepressant", "TSH, CBC if indicated"]
    },
    "medications": {
      "first_line": [
        {"class": "SSRI", "agents": [
          {"name": "Sertraline", "adult_dose_range": "50–200 mg/day"},
          {"name": "Escitalopram", "adult_dose_range": "10–20 mg/day"}
        ]},
        {"class": "SNRI", "agents": [
          {"name": "Venlafaxine XR", "adult_dose_range": "75–225 mg/day"}
        ]}
      ],
      "second_line": [
        {"class": "Atypical", "agents": [
          {"name": "Bupropion XL", "adult_dose_range": "150–450 mg qAM"},
          {"name": "Mirtazapine", "adult_dose_range": "15–45 mg qHS"}
        ]}
      ]
    },
    "psychotherapies": ["CBT", "Behavioral activation", "IPT"],
    "special_populations": ["Perinatal: weigh SSRI risks/benefits", "Elderly: lower doses"],
    "references": ["APA MDD Guideline", "NICE NG222", "FDA labels"],
    "disclaimer": "Educational reference for clinicians; verify in full label/guideline."
  },
  {
    "query_understanding": "GAD adult: dx + meds",
    "diagnosis": {
      "name": "Generalized Anxiety Disorder",
      "codes": {"ICD10": "F41.1", "ICD11": "6B00"},
      "core_criteria_summary": "≥6 months excessive anxiety/worry most days; ≥3 of restlessness, fatigue, concentration, irritability, muscle tension, sleep disturbance; impairment.",
      "differential": ["Hyperthyroidism", "Substance/med-induced", "MDD", "OCD"],
      "screeners": [{"name": "GAD-7", "use": "severity & monitoring", "cutoffs": "5/10/15 = mild/mod/severe"}],
      "workup_considerations": ["TSH if indicated", "Caffeine/substances", "Rule out panic disorder"]
    },
    "medications": {
      "first_line": [
        {"class": "SSRI", "agents": [
          {"name": "Escitalopram", "adult_dose_range": "10–20 mg/day"},
          {"name": "Sertraline", "adult_dose_range": "50–200 mg/day"}
        ]},
        {"class": "SNRI", "agents": [
          {"name": "Duloxetine", "adult_dose_range": "30–120 mg/day"},
          {"name": "Venlafaxine XR", "adult_dose_range": "75–225 mg/day"}
        ]}
      ],
      "second_line": [
        {"class": "Atypical", "agents": [
          {"name": "Buspirone", "adult_dose_range": "15–60 mg/day"}
        ]},
        {"class": "Adjuncts", "agents": [
          {"name": "Hydroxyzine", "adult_dose_range": "25–50 mg PRN"},
          {"name": "Propranolol (performance)", "adult_dose_range": "10–40 mg PRN"}
        ]}
      ]
    },
    "psychotherapies": ["CBT with worry exposure", "Mindfulness-based CBT"],
    "special_populations": ["Elderly: fall risk, anticholinergic burden", "Avoid routine benzodiazepines"],
    "references": ["APA Anxiety Guideline", "NICE CG113", "FDA labels"],
    "disclaimer": "Educational reference for clinicians; verify in full label/guideline."
  }
]
